【制药网 行业动态】在 2024 年，中国药品行业的投融资市场呈现出一番独特的景象。据相关数据统计，全年共发生 300 起投融资事件，涉及金额约 517.81 亿元。这一数据不仅反映了资本市场对药品行业的持续关注，更揭示了行业内部正在发生的深刻变革与发展趋势。在这 300 起投融资事件中，绿叶制药、箕星医药、先声再明、华北制药金坦生物、安济盛生物、普方生物、成都通瑞生物、剂泰医药、信诺维、华诺泰...
Source Link【制药网 行业动态】在 2024 年，中国药品行业的投融资市场呈现出一番独特的景象。据相关数据统计，全年共发生 300 起投融资事件，涉及金额约 517.81 亿元。这一数据不仅反映了资本市场对药品行业的持续关注，更揭示了行业内部正在发生的深刻变革与发展趋势。在这 300 起投融资事件中，绿叶制药、箕星医药、先声再明、华北制药金坦生物、安济盛生物、普方生物、成都通瑞生物、剂泰医药、信诺维、华诺泰...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.